F9 Specific Neutra™ Antibody Products

Are extended timelines in antibody development or challenges in managing coagulation-related diseases hindering your progress? Creative Biolabs' F9 specific Neutra™ antibody products overcome these obstacles through advanced recombinant engineering and rigorous functional validation, empowering rapid therapeutic development and precise disease targeting.

Introduction to F9

Coagulation factor IX (F9), a vitamin K-dependent serine protease, is essential for the intrinsic pathway of blood coagulation. Synthesized predominantly in the liver, F9 circulates as an inactive zymogen and is activated via proteolytic cleavage by factor XIa or the tissue factor–factor VIIa complex. Genetic mutations in the F9 gene are linked to hemophilia B, a recessive X-linked bleeding disorder.

• Structural Insights

F9 comprises multiple domains critical for its function: an N-terminal γ-carboxyglutamic acid (Gla) domain, two epidermal growth factor (EGF)-like domains, and a C-terminal serine protease domain. The Gla domain mediates calcium-dependent binding to phospholipid membranes, while the protease domain executes cleavage of factor X to propagate coagulation. Post-translational modifications, including γ-carboxylation and glycosylation, are vital for F9 stability and activity. Structural studies reveal that conformational changes during activation expose the active site, enabling substrate recognition.

• Related Signaling Pathways

F9 is a key component of the intrinsic coagulation cascade. Upon vascular injury, F9 is activated (FIXa) and forms a complex with factor VIIIa on platelet surfaces, amplifying thrombin generation. This pathway intersects with inflammatory and complement systems, where dysregulated coagulation exacerbates thrombotic disorders like deep vein thrombosis or disseminated intravascular coagulation.

Fig.1 FIX and the classic coagulation cascade.¹

• Pathological Relevance

Hemophilia B, characterized by insufficient functional F9, leads to spontaneous bleeding, joint damage, and life-threatening hemorrhage. Additionally, acquired F9 inhibitors—autoantibodies neutralizing F9—complicate treatment in both congenital and autoimmune conditions. Understanding F9 structure-function relationships is critical for developing therapies to restore hemostatic balance.

Applications of Anti-F9 Neutralizing Antibodies

• Therapeutic Development for Hemophilia B

Neutralizing antibodies are pivotal in characterizing F9 biologics or gene therapies. By selectively inhibiting endogenous F9, they validate the efficacy of recombinant F9 or engineered variants in preclinical models, accelerating translational research.

• Management of Acquired Inhibitors

In patients with anti-F9 autoantibodies, neutralizing antibodies serve as positive controls in diagnostic assays to quantify inhibitor titers. This supports personalized treatment strategies, such as immune tolerance induction or bypass therapies.

• Surgical and Trauma-Related Bleeding

Anti-F9 antibodies facilitate the study of coagulation dynamics in trauma settings. By modulating F9 activity, researchers can simulate hypo- or hypercoagulable states to optimize interventions like prothrombin complex concentrates.

• Thrombosis Research

Excessive F9 activity contributes to thrombotic disorders. Neutralizing antibodies are utilized to dissect F9's role in thrombosis models, enabling the development of targeted anticoagulants with reduced bleeding risks compared to traditional therapies.

• Vaccine Efficacy Evaluation

In hemophilia B gene therapy trials, anti-F9 antibodies assess immune responses to viral vectors or transgene products, ensuring therapeutic safety and durability.

Our Anti-F9 Neutralizing Antibodies

Creative Biolabs' anti-F9 antibodies are engineered for high specificity and neutralizing potency. These antibodies bind critical epitopes within the Gla or protease domains, blocking F9 activation or its interaction with cofactors. Validated in ELISA, Western blot, and functional clotting assays, they enable:

- Quantification of F9 levels in plasma or cell models.

- Inhibition studies to evaluate F9-dependent coagulation.

- Development of diagnostic assays for hemophilia B and inhibitor screening.

Creative Biolabs delivers rigorously validated F9-specific antibodies to advance research in coagulation disorders, therapeutic development, and diagnostic innovation. Our products combine high affinity, batch-to-batch consistency, and tailored support for diverse experimental needs.

Contact our team today to discuss your project requirements and explore how our antibody products can accelerate your breakthroughs.

REFERENCE

1. Top, Oguz, et al. "Critical evaluation of strategies for the production of blood coagulation factors in plant-based systems." Frontiers in plant science 10 (2019): 261. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fpls.2019.00261